Should I buy Herbalife stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring Herbalife's market performance for more than three years. Every month, hundreds of thousands of users across Canada rely on us to break down market trends and highlight the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never received, and will never accept, compensation from Herbalife.

What is Herbalife?

How much is Herbalife stock?

The price of Herbalife stock is falling this week. As of April 30, 2025, HLF trades at $7.05, reflecting a 24-hour decline of 0.35% and a weekly drop of 1.58%. The company’s market capitalization stands at approximately $715 million, with a 3-month average daily volume of 2.6 million shares. Herbalife’s P/E ratio is an attractive 2.82, though it currently pays no dividend (0% yield), and its beta is 1.02, indicating average market volatility. Investors should be aware that recent price swings highlight both risks and potential opportunities in this dynamic sector.

Our full analysis on Herbalife stock

Having meticulously reviewed Herbalife Ltd.’s latest quarterly results and dissected the past three years of stock price behaviour, we applied our proprietary blend of financial, technical, and market competitor analytics to evaluate the company’s near-term and long-range potential. Drawing on robust data and a multidimensional approach, we find ourselves at a critical inflection point for Herbalife. So, why might Herbalife stock once again become a strategic entry point into the global health and wellness sector in 2025?

Recent Performance and Market Context

Despite broad volatility within U.S. and global equity markets over the past year, Herbalife (NYSE: HLF) has demonstrated periods of notable resilience amidst a challenging landscape for consumer brands. As of April 30, 2025, the stock trades at $7.05—well within its 52-week range of $5.04 to $12.79—following a modest YTD gain of 5.31%. While a 1-year price decline of -18.55% might initially seem discouraging, it’s important to contextualize this against heightened sector competition and a macroeconomic backdrop characterized by shifting consumer health trends and revived regulatory focus.

Positive recent events have injected renewed confidence. Notably, an insider purchase of nearly $500,000 by outgoing CEO Michael Johnson in February 2025 signaled direct management conviction, while the March announcement of acquisitions (Pro2col, Pruvit, and Link BioSciences) underscored determined strategic expansion. Additionally, Herbalife’s global footprint—operating in over 90 markets—offers geographic diversification that many Canadian investors will value as a stabilizing factor.

Favourable North American macroeconomic signals—especially strong U.S. job growth and persistently solid consumer spending in health and wellness—are providing a tailwind to demand in Herbalife’s core product categories. As regulatory clarity improves in several markets, direct selling models are regaining investor credibility, further supporting sector sentiment.

Technical Analysis

Technical signals point towards a potential inflection—making this level especially intriguing for market participants seeking a tactical entry. Currently, the Relative Strength Index (RSI) sits at 45.23, which suggests neither overbought nor oversold conditions and signals the possibility of stabilization. The MACD (-0.34) and Williams %R (-61.79) both issue bullish signals, indicating underlying momentum for a short-term reversal.

Short-term momentum is further supported by the 5-day simple moving average ($6.79), flashing a buy signal as it hovers below the current price. While medium- and longer-term moving averages (20-, 50-, 100-, 200-day) provide a more restrained perspective—indicating ongoing medium-term pressure—the stock is presently consolidating above crucial support levels at $6.52, $6.36, and $6.16. Resistance sits just above at $6.87, $7.07, and particularly $7.22, with a break above these thresholds likely to trigger additional technical buying.

In sum, while some caution is warranted in recognizing a still-volatile structure, the present configuration may be consistent with the early phase of a bottoming process. This could set the stage for a new medium-term uptrend as further catalysts materialize.

Fundamental Analysis

Herbalife’s fundamentals, even under conservative scrutiny, seem to justify renewed interest. The company continues to generate significant revenues, reporting $4.99 billion (TTM) and delivering net income of $254.3 million for the most recent trailing twelve months—a robust achievement given macro headwinds. EPS of $2.50 underpins strikingly attractive valuation multiples, with a trailing P/E ratio of just 2.82 and a forward P/E of 3.37—well below the sector average.

Adjusted EBITDA margins have expanded to 12.4% as of Q4 2024, up 340 basis points year-over-year, reflecting disciplined cost management and improving profitability. While Q1 2025 consensus expects a modest YoY revenue pullback of -2.8%, the full-year 2024 EBITDA guidance for 2025 at $620 million demonstrates management’s confidence in sustained cash flow generation.

• Strong global presence secures long-term brand relevance and reduces exposure to isolated regional trends.
• Innovation and strategic expansion—through both organic growth and selective acquisition (Pro2col, Pruvit, Link BioSciences)—highlight a proactive approach to product pipeline renewal and competitive positioning.
• Financial flexibility is assured by a healthy cash position ($415.3 million), enabling further investment in R&D, digital infrastructure, and distributor incentives.

The price-to-sales ratio of just 0.14, coupled with an EV/EBITDA of 5.44, suggests that the market may be undervaluing Herbalife’s capacity for sustained value creation, especially when compared to global peers.

Volume and Liquidity

Herbalife’s average daily trading volume of 2.6 million shares speaks to a high level of liquidity—critical for Canadian investors and institutions seeking reliable entry and exit points. Consistent volume reflects robust market confidence; the stock’s float supports dynamic valuation, with movements responsive to both fundamental developments and technical breakouts.

A market cap of $715.46 million positions Herbalife as a credible mid-cap candidate for diversified portfolios, while maintaining ample daily liquidity to facilitate active trading strategies and institutional flows. This trading profile remains supportive of swift price discovery and accurate trend recognition.

Catalysts and Positive Outlook

• CEO Succession: The May 2025 leadership transition to Stephan Gratziani—a leader with deep operational experience and distributor network empathy—signals a strategic pivot, from traditional direct selling towards a technology-enabled, consumer-centric business.
• Acquisitions: The integration of Pro2col and Pruvit, as well as majority control of Link BioSciences, is expected to broaden the product offering and inject fresh innovation into Herbalife’s portfolio. This positions the company to capitalize on evolving health and wellness trends, especially in targeted product niches with higher margin potential.
• Insider Confidence: Substantial insider buying by executive leadership provides a tangible vote of confidence in future performance and alignment with shareholder interests.
• ESG Initiatives: Ongoing efforts toward product transparency, sustainable sourcing, and global community engagement reinforce the brand among increasingly discerning consumers and large institutional investors.
• Sector Growth: North America’s robust consumption backdrop and Asia-Pacific’s rising health awareness contribute to a favorable upward context—a boon for companies with scale, brand equity, and differentiated product lines.

Moreover, anticipated regulatory stabilization in legacy markets and potential entry into new geographies create a rich backdrop for medium-term outperformance.

Investment Strategies

• Short-term: Those seeking tactical entries may find the stock’s consolidation above support levels ($6.52 – $6.36) and encouraging MACD/Williams %R readings to represent an excellent opportunity for rebound plays. Upcoming Q1 earnings could serve as a volatility catalyst and potential technical inflection point.
• Medium-term: Investors may consider accumulating shares as the leadership transition unfolds and integration synergies from acquisitions become more visible, positing a thesis around operational uplift and margin expansion over the next two to four quarters.
• Long-term: Herbalife’s global scale, recurring revenue model, and disciplined capital allocation position the company as a potential compounder in a structurally expanding sector. Entry near the lower end of its historical range could yield compelling risk-adjusted returns, particularly for those allocating to the health and wellness theme within a diversified Canadian portfolio.

Ideal positioning may be captured by scaling in around well-established support levels, or by anticipating technical confirmation as resistance (notably $7.22) is decisively overtaken.

Is it the Right Time to Buy Herbalife?

Synthesizing key strengths—Herbalife’s deeply discounted valuation multiples, expanding profit margins, global reach, and fresh leadership vision—brings us to an inflection point where the fundamentals seem to justify a renewed, positive outlook. Technical signals are mixed but increasingly constructive, while sector tailwinds and company-specific catalysts are converging just as the stock consolidates at historically attractive levels.

Given the proactive approach to innovation, strategic acquisitions, and the evident conviction demonstrated by management insiders, Herbalife appears to be entering a new bullish phase. Although challenges remain—particularly in sustaining revenue momentum—the combination of low valuation, solid liquidity, and imminent catalysts may position the stock for material outperformance in the coming quarters.

For Canadian investors seeking exposure to a global leader in health and wellness, Herbalife’s current profile seems to represent an excellent opportunity for serious consideration. As the new leadership team assumes command and transformative initiatives take shape, Herbalife may well be on the cusp of renewed relevance and sustained value creation—inviting investors to re-examine its place within a forward-looking portfolio focused on upside in 2025 and beyond.

How to buy Herbalife stock in Canada?

Buying Herbalife shares has never been easier or more secure for Canadian investors. Thanks to regulated online brokers, you can purchase Herbalife (HLF) stock directly from your computer or smartphone in minutes. Investors typically have two main options: buying Herbalife shares outright (also known as spot or cash buying), or trading Contracts for Difference (CFDs) to speculate on price movements with leverage. Each method has its own advantages, risk profile, and fee structure. Below, we explain both approaches in detail. For a side-by-side comparison of leading brokers, see our broker comparison tool further down the page.

Spot Buying

Spot, or cash, buying means you purchase Herbalife shares directly on an exchange and become a part-owner of the company. In Canada, this is usually done via a registered online brokerage. When you buy shares this way, your main costs are a fixed commission per order—often ranging from $5 to $10 CAD, depending on the broker.

Concrete Example

Suppose the current price of Herbalife stock is $7.05 USD per share. With a $1,000 CAD investment and an assumed exchange rate of 1.36 (1 USD ≈ 1.36 CAD), that's roughly $735 USD after currency conversion. You can then buy about 104 shares ($735 ÷ $7.05 = ~104), and after including a typical $5 CAD commission, your total cost is just over $1,000 CAD.

Gain Scenario

If the share price rises by 10%, your shares would now be valued at about $1,100 CAD (excluding currency fluctuations and commissions from selling).

Result: +$100 gross gain, or a 10% return on your investment.

Trading via CFD

CFD (Contract for Difference) trading allows you to speculate on the price movements of Herbalife shares without actually owning the underlying stock. This method is available through certain online brokers that offer leveraged trading. Instead of paying a fixed commission, you typically pay a spread (the difference between buy and sell price), and overnight financing fees if your position remains open more than a day.

Example with leverage

With a $1,000 CAD stake and 5x leverage, your market exposure becomes $5,000 CAD. If Herbalife’s stock price rises by 8%, your position gains not just 8%, but 8% × 5 = 40%.

Result: +$400 gain on a $1,000 investment (before fees and currency effects).

CFDs can amplify both gains and losses, so they suit more experienced traders who actively manage their positions.

Final Advice

Before you invest in Herbalife or any stock, take time to compare brokers—fees, commissions, platforms, and account conditions can vary widely and have a real impact on your returns. Whether you choose to buy shares for the long-term or trade via CFDs for short-term opportunities ultimately depends on your financial goals, risk tolerance, and investment style. For an overview of leading brokers and platforms available to Canadians, be sure to consult our broker comparison further down this page.

Platforms

Minimum Deposit

Discover

#1

Tier 1 regulation, including ASIC and FSA

#1

Star Trader

4.9

Minimum Deposit

$50

Discover

with our partner Star Trader

#2

Broker specializing in Forex and CFDs

#2

IFC Markets

4.8

Minimum Deposit

$1

Discover

with our partner IFC Markets

#3

Broker regulated since 2006

#3

Avatrade

4.8

Minimum Deposit

$100

Discover

with our partner Avatrade

Our 7 tips for buying Herbalife stock

The latest news about Herbalife

Herbalife’s leadership transition sees Stephan Gratziani, a long-time executive with distributor experience, assuming the CEO role on May 1, 2025. This appointment is particularly significant as Gratziani’s direct sales background aligns closely with Herbalife’s operational DNA, and signals a renewed commitment to empowering distributors—a core driver of Herbalife’s business both globally and in the Canadian market. His stated vision to integrate advanced health and wellness technologies with the existing direct selling infrastructure could position the company to better address evolving consumer preferences, including those in Canada’s active and diverse wellness sector.

The company’s recent acquisition initiatives—including assets from Pro2col, Pruvit, and Link BioSciences—reflect a strategic effort to expand and diversify Herbalife’s product portfolio. As Canada continues to see robust demand for innovative health and wellness products, such acquisitions may enable Herbalife to introduce new offerings to Canadian distributors and customers, strengthening its competitive stance. These expansion moves, coming amid heightened competition in the industry, could boost revenue channels, improve product differentiation, and support Herbalife’s market share in Canada and other key geographies.

Recent insider buying activity from outgoing Chairman and CEO Michael Johnson demonstrates executive confidence in the company’s future direction. Johnson’s purchase of nearly $500,000 worth of Herbalife shares in February 2025 is widely regarded as a positive signal among institutional investors and market analysts. For Canadian investors and distributors, such demonstrated belief by company leadership can reinforce perceptions of Herbalife’s stability and long-term growth prospects, particularly as it navigates leadership changes and new market opportunities.

Herbalife maintains a strong financial position, with $415.3 million in cash and healthy EBITDA margins supporting ongoing operations and investments. These metrics are especially relevant in the current environment with economic uncertainty and regulatory scrutiny impacting the broader direct selling sector, including in Canada. The company’s low valuation multiples, such as a P/E ratio of 2.82, suggest potential undervaluation and leave room for share price appreciation if revenue stabilization and growth initiatives bear fruit, offering a constructive outlook for Canadian investors considering exposure to the stock.

Short-term technical indicators, including MACD and Williams %R, suggest potential buying opportunities amid broader market caution. While the stock remains under pressure in the medium term, as reflected by key moving averages, the appearance of short-term buy signals may appeal to Canadian traders and fund managers seeking timely entry points. The upcoming Q1 2025 earnings release, coupled with the new CEO’s inaugural strategic commentary, is expected to serve as a pivotal near-term catalyst, with particular implications for market sentiment and Herbalife’s operational momentum in the Canadian market.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.